Predictive biomarkers of benefit to axitinib plus avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC)

被引：0
作者：
Hoff, Camilla Oliveira
McGrail, Daniel
Heeke, Simon
de Sousa, Luana Guimaraes
Li, Kaiyi
Bell, Diana
Mitani, Yoshitsugu
Marques-Piubelli, Mario L.
Cortez, Maria Angelica
Lin, Shiaw-Yih
Elamin, Yasir Y.
El-Naggar, Adel K.
Ferrarotto, Renata
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Cleveland Clin, Cleveland, OH USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6096
引用
收藏
页数：1
相关论文
共 50 条
[41]   Updated results of the Tide-A study evaluating avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients with metastatic renal cell carcinoma (mRCC). [J].
Arduini, Chiara ;
Ciccarese, Chiara ;
Acunzo, Alessandro ;
Perrino, Matteo ;
Maruzzo, Marco ;
Verzoni, Elena ;
Accettura, Caterina ;
Bonomi, Lucia ;
Buttigliero, Consuelo ;
Cremante, Malvina ;
Pipitone, Stefania ;
Scartozzi, Mario ;
Masini, Cristina ;
Mollica, Veronica ;
Primi, Francesca ;
Strusi, Alessandro ;
Buti, Sebastiano ;
Zucali, Paolo Andrea ;
Fantinel, Emanuela ;
Iacovelli, Roberto .
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) :551-551
[42]   Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study [J].
Zhu, Guopei ;
Zhang, Lin ;
Dou, Shengjin ;
Li, Rongrong ;
Li, Jiang ;
Ye, Lulu ;
Jiang, Wen ;
Dong, Minjun ;
Ruan, Min ;
Yang, Wenjun ;
Zhang, Chenping .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[43]   LOCAL CONTROL FOLLOWING COMBINATION HYPOFRACTIONATED RADIOTHERAPY AND PEMBROLIZUMAB IN A PHASE II TRIAL OF RECURRENT OR METASTATIC ADENOID CYSTIC CARCINOMA PATIENTS [J].
Bang, Andrew ;
Mahmood, Umair ;
Chen, Yu-Hui ;
Mak, Raymond H. ;
Lorch, Jochen H. ;
Hanna, Glenn J. ;
Sridharan, Vishwajith ;
Busse, Paul M. ;
Willers, Henning ;
Mamon, Harvey J. ;
Yoo, Hyung-Jin ;
Pai, Sara I. ;
Wirth, Lori J. ;
Haddad, Robert I. ;
Chau, Nicole G. ;
Schoenfeld, Jonathan D. .
RADIOTHERAPY AND ONCOLOGY, 2019, 139 :S26-S27
[44]   Local Control following Combination Hypofractionated Radiotherapy and Pembrolizumab in A Phase II Trial of Recurrent or Metastatic Adenoid Cystic Carcinoma Patients [J].
Bang, A. ;
Mahmood, U. ;
Chen, Y. H. ;
Mak, R. H. ;
Lorch, J. ;
Hanna, G. J. ;
Sridharan, V. ;
Busse, P. M. ;
Willers, H. ;
Mamon, H. J. ;
Yoo, H. J. ;
Pai, S. I. ;
Wirth, L. ;
Haddad, R. I. ;
Chau, N. ;
Schoenfeld, J. D. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01) :E363-E363
[45]   Phase II study of nivolumab and ipilimumab for treatment of metastatic/recurrent adenoid cystic carcinoma (ACC) of all anatomic sites of origin and other malignant salivary gland tumors [J].
Chae, Young Kwang ;
Duan, Richard ;
Chung, Liam Il-Young ;
Oh, Youjin ;
Matsangou, Maria ;
Agulnik, Mark ;
Villaflor, Victoria ;
Mahalingam, Devalingam .
CANCER RESEARCH, 2023, 83 (08)
[46]   ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort [J].
Ho, A. L. ;
Bowles, D. W. ;
Even, C. ;
Hao, D. ;
Kang, H. ;
Metcalf, R. ;
Muzaffar, J. ;
Oliva, M. ;
Perez, C. A. ;
Popovtzer, A. ;
Rodriguez, C. P. ;
Stemmer, S. M. ;
Van Herpen, C. M. ;
Winquist, E. ;
Wirth, L. J. ;
Worden, F. P. ;
Xia, B. ;
Gordon, G. ;
Gordon, G. B. ;
Ferrarotto, R. .
ANNALS OF ONCOLOGY, 2021, 32 :S803-S804
[47]   Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). [J].
Chow, Laura Quan Man ;
Mehra, Ranee ;
Haddad, Robert I. ;
Mahipal, Amit ;
Weiss, Jared ;
Berger, Raanan ;
Eder, Joseph Paul ;
Burtness, Barbara ;
Tahara, Makoto ;
Keam, Bhumsuk ;
Le, Dung T. ;
Muro, Kei ;
Geva, Ravit ;
Chung, Hyun Cheol ;
Lin, Chia-Chi ;
Ayers, Mark ;
Aurora-Garg, Deepti ;
Lunceford, Jared K. ;
Cheng, Jonathan D. ;
Seiwert, Tanguy Y. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[48]   Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab plus axitinib (A plus Ax) or sunitinib (S): Results from JAVELIN Renal 101 [J].
Grimm, M-O. ;
Oya, M. ;
Choueiri, T. K. ;
Schmidinger, M. ;
Quinn, D. I. ;
Mescam, G. Gravis ;
Verzoni, E. ;
Van den Eertwegh, A. J. M. ;
di Pietro, A. ;
Mariani, M. ;
Wang, J. ;
Thomaidou, D. ;
Albiges, L. .
ANNALS OF ONCOLOGY, 2021, 32 :S690-S691
[49]   Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab plus axitinib (A plus Ax) or sunitinib (S): results from JAVELIN Renal 101 [J].
Grimm, Marc-Oliver ;
Oya, Mototsugu ;
Choueiri, Toni K. ;
Schmidinger, Manuela ;
Quinn, David ;
Gravis-Mescam, Gwenaelle ;
Verzoni, Elena ;
Van den Eertwegh, Alfonsus ;
Di Pietro, Alessandra ;
Mariani, Mariangela ;
Wang, Jing ;
Thomaidou, Despina ;
Albiges, Laurence .
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) :100-100
[50]   Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study [J].
Iacovelli, R. ;
Ciccarese, C. ;
Bersanelli, M. ;
Zucali, P. A. ;
Fantinel, E. ;
Bimbatti, D. ;
Verzoni, E. ;
Accettura, C. ;
Bonomi, L. ;
Buttigliero, C. ;
Fornarini, G. ;
Pipitone, S. ;
Atzori, F. ;
Masini, C. ;
Massari, F. ;
Primi, F. ;
Buti, S. ;
Perrino, M. R. A. ;
Pafumi, S. ;
Tortora, G. .
ANNALS OF ONCOLOGY, 2023, 34 :S1013-S1013
12345